Viral Inactivation

Global Viral Inactivation Market to Reach US$1.5 Billion by 2030

The global market for Viral Inactivation estimated at US$781.3 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 11.5% CAGR and reach US$865.8 Million by the end of the analysis period. Growth in the Systems segment is estimated at 12.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$214.8 Million While China is Forecast to Grow at 11.1% CAGR

The Viral Inactivation market in the U.S. is estimated at US$214.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$234.5 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.1% and 9.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Viral Inactivation Market - Key Trends & Drivers Summarized

Why Is Viral Inactivation Crucial for Biopharmaceutical Manufacturing?
Viral inactivation has become a cornerstone of biopharmaceutical production, ensuring that biologic drugs, including vaccines, monoclonal antibodies, and plasma-derived therapies, meet the highest safety standards. Regulatory agencies such as the FDA, EMA, and WHO have stringent guidelines mandating viral inactivation to prevent contamination and ensure patient safety. With the increasing reliance on biologics for the treatment of chronic diseases and autoimmune disorders, the demand for effective viral inactivation methods is soaring. Traditional methods such as solvent/detergent treatment, heat inactivation, and low pH inactivation continue to be widely used, while novel technologies, including UV-C irradiation and nanotechnology-based viral removal systems, are gaining traction to enhance the efficiency of bioprocessing workflows.

What Innovations Are Shaping the Future of Viral Inactivation?
Technological innovations are revolutionizing viral inactivation techniques, improving process efficiency and ensuring compliance with evolving regulatory requirements. High-throughput and automated viral inactivation platforms are reducing process variability and improving scalability in large-scale biopharmaceutical production. The integration of AI and machine learning into bioprocessing workflows is optimizing inactivation parameters, enhancing reproducibility, and minimizing the risk of batch failures. Single-use bioprocessing systems are further driving advancements in viral inactivation, providing flexibility and cost-effectiveness while reducing cross-contamination risks. Additionally, advancements in filtration and chromatography techniques are enabling more precise and efficient viral removal without compromising product yield and quality.

How Is the Biopharmaceutical Industry Driving Demand for Viral Inactivation?
The surge in monoclonal antibody and recombinant protein production has significantly boosted demand for viral inactivation solutions, as pharmaceutical companies seek to enhance product safety and accelerate regulatory approvals. The increasing development of cell and gene therapies is also reinforcing the need for advanced viral clearance and inactivation technologies to ensure the integrity of these highly sensitive therapies. Furthermore, the rise of contract development and manufacturing organizations (CDMOs) in biopharmaceutical production is increasing outsourcing of viral inactivation services, allowing biopharma firms to focus on drug development while ensuring stringent safety standards. With global vaccine development efforts intensifying, particularly in response to pandemics and emerging infectious diseases, viral inactivation remains a fundamental step in ensuring vaccine safety and efficacy.

The growth in the viral inactivation market is driven by several factors, including the expanding biologics pipeline, advancements in inactivation technologies, and increasing regulatory emphasis on biopharmaceutical safety. The adoption of single-use bioprocessing and automated viral clearance platforms is accelerating process efficiency while reducing contamination risks. Additionally, the rise of contract manufacturing is propelling demand for specialized viral inactivation services, creating new growth opportunities in the sector. The growing need for robust inactivation techniques in cell and gene therapy production is further fueling market expansion. As biopharmaceutical companies continue to invest in next-generation therapeutics, the demand for innovative and scalable viral inactivation solutions is expected to rise, ensuring sustained market growth.

SCOPE OF STUDY:

The report analyzes the Viral Inactivation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Vaccines and Therapeutics, Stem Cell Products, Blood and Blood Products, Tissue/ Tissue Products, Cellular and Gene Therapy); Product (Kits & Reagents, Systems, Services)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Charles River Laboratories International, Inc.
• Clean Cells Inc.
• Danaher Corporation
• Merck KgaA
• Parker Hannifin Corporation
• Rad Source Technologies, Inc.
• Sartorius AG
• SGS Group (SGS SA)
• Texcell, Inc.
• V.I.P.S. SA
• WuXi AppTec Group

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.